aptivus
Pharmaranks rates Aptivus 3.6/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Aptivus (Tipranavir) is a medication used to treat Acquired Immunodeficiency Syndrome.
Tipranavir · by Boehringer Ingelheim
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Tipranavir
- Form
- Capsule
- Strength
- Tipranavir 250MG
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- acquired immunodeficiency syndrome
- Manufacturer
- Boehringer Ingelheim
- FDA application
- NDA021814
May treat (source: NIH RxClass)
Dosage forms
Capsule
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Aptivus treat?
- Aptivus (Tipranavir) may be used to treat acquired immunodeficiency syndrome, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Aptivus rated?
- pharmaranks gives Aptivus a composite score of 3.6 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Aptivus?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Aptivus. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Aptivus?
- Aptivus is marketed by Boehringer Ingelheim. You can see Boehringer Ingelheim's full profile, rating, and other products on pharmaranks.
- Is Aptivus a brand-name or generic drug?
- Aptivus is a brand-name product with the active ingredient Tipranavir.
- Is Aptivus available over the counter?
- No. Aptivus is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Aptivus come in?
- Aptivus is currently marketed as capsule, per the FDA's National Drug Code Directory.
- Is Aptivus FDA-registered?
- Aptivus is on record with the U.S. FDA under application number NDA021814. You can verify this on its official FDA label.
- Has Aptivus been recalled by the FDA?
- Aptivus has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Aptivus safe?
- There's no single safe-or-not verdict. pharmaranks gives Aptivus a recall-safety score of 72/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about TIPRANAVIR
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 1,015 reports naming TIPRANAVIR — the active ingredient in Aptivus, and the FDA flagged 97% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- nausea139 reports
- vomiting132 reports
- pneumonia123 reports
- hepatotoxicity105 reports
- cholelithiasis104 reports
- hepatic enzyme increased101 reports
- oedema peripheral101 reports
- schizophrenia101 reports
Read these as a signal, not a rate. A report does not mean TIPRANAVIR caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 26, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
reyataz
Atazanavir Sulfate
vemlidy
Tenofovir Alafenamide Fumarate
viread
Tenofovir Disoproxil Fumarate
lamivudine
Lamivudine
nevirapine
Nevirapine
epivir
Lamivudine
Compare Aptivus head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
aptivus
72/100